ALL patients aged 55 years or older were treated with steroids during one week and Ph+ve cases were then offered a specific therapy including an induction treatment with steroids, cyclophosphamide, daunorubicin and vincristine, followed, irrespective of response to induction chemotherapy, by imatinib, 600 mg daily, combined with intermittent steroids during 2 months. Patients in complete response (CR) were then given 10 blocks of alternating chemotherapy, including 2 additional two-month blocks of imatinib, for a total treatment duration of 2 years. Therapy of occult central nervous system leukemia included 5 intrathecal injections of methotrexate and cranial irradiation. Duration of therapy : 2 years.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
30
Xavier THOMAS
Lyon, France
Impact of Imatinib on survival in elderly patients with Ph+ALL
Tolerance of Imatinib
Complete remission rate
Minimal Residual Disease after Imatinib treatment
Leukemia free survival
Impact of steroids given before starting chemotherapy
Study of potential resistance mechanisums to Imatinib
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.